Skip to content
Dosage Guide · FDA-approved drug

Tirzepatide Dosage: Zepbound & Mounjaro

Last updated May 19, 2026 · Reviewed by Grey Peptides Editorial Board · ✓ Based on FDA labeling

← Tirzepatide encyclopedia entry · Compare: Semaglutide dosage · Semaglutide vs Tirzepatide

📋 Key takeaways

Tirzepatide is an FDA-approved prescription medicine — a dual GIP/GLP-1 agonist sold as Zepbound (obesity) and Mounjaro (type 2 diabetes). Both use the same once-weekly injection and the same stepwise titration.

Dosing starts at 2.5 mg and increases by 2.5 mg every four weeks toward a maximum of 15 mg weekly. The 2.5 mg start is a tolerance dose, not a treatment dose. Many people get a strong result at an intermediate step (10 or 12.5 mg) without needing the maximum.

This summarizes the labeled schedule for education. Your prescriber sets and adjusts the actual dose based on tolerability and response.


The titration schedule (Zepbound & Mounjaro)

WeeksDoseFrequency
1–42.5 mgOnce weekly (starting/ramp dose)
5–85 mgOnce weekly
9–127.5 mgOnce weekly
13–1610 mgOnce weekly
17–2012.5 mgOnce weekly
21+15 mgOnce weekly (maximum)

→ Plan this schedule in the GLP-1 Titration Planner — pick a target dose and start date for a dated, week-by-week plan and an escalation chart.

The label calls for at least four weeks at each dose before stepping up by 2.5 mg. The approved maintenance doses are 5, 10, and 15 mg — so an effective dose can sit at any of those, not only the maximum. Compared with semaglutide, tirzepatide's schedule has more steps, which gives prescribers finer control to balance results against tolerability.


Why the slow ramp

As with all incretin drugs, the gradual increase exists to limit gastrointestinal side effects — nausea, diarrhea, vomiting, constipation — which peak when the dose rises. Holding at a step longer, or backing down one level, is a normal way to manage tolerability. The 2.5 mg starting dose isn't expected to drive much weight loss; it's there to ease the body in.


Practical dosing notes

  • Timing: once weekly, the same day each week, any time of day, with or without food. The day can be changed if doses stay at least 72 hours (3 days) apart.
  • Injection sites: abdomen, thigh, or upper arm, rotating sites.
  • Missed dose: per the label, take it within 4 days (96 hours) of the missed dose; if more time has passed, skip it and resume the weekly schedule.
  • Forms: branded tirzepatide comes in single-dose pens or vials. Compounded vial forms require measurement — see the Reconstitution Calculator, and note the changing rules on compounded GLP-1s in the Regulatory Tracker.
  • Stopping: weight regain is common after discontinuation; it's a chronic treatment, not a short course.

Side effects & safety, briefly

Common effects are gastrointestinal and ease after titration; in trials, tirzepatide's nausea rates were somewhat lower than semaglutide's. It carries the class warnings (including a boxed warning regarding thyroid C-cell tumors seen in rodents, plus pancreatitis and gallbladder cautions) that your prescriber screens for. For combinations and interactions, see the GLP-1 drug interactions guide. This is a dosing summary, not a replacement for the full prescribing information or clinical guidance.


Frequently asked questions

Do I have to reach 15 mg?

No. 5, 10, and 15 mg are all approved maintenance doses. The right dose is the lowest one that gives a good response with tolerable side effects — a prescriber's decision.

Is Zepbound dosing different from Mounjaro?

The titration and doses are the same; the brands differ by approved indication (Zepbound for obesity, Mounjaro for type 2 diabetes).

How does this compare to semaglutide dosing?

Different molecule and scale — tirzepatide runs 2.5–15 mg with six steps; semaglutide (Wegovy) runs 0.25–2.4 mg with five. See Semaglutide dosage and the full comparison.


Sources

  1. FDA prescribing information — Zepbound (tirzepatide injection), obesity dosing and titration.
  2. FDA prescribing information — Mounjaro (tirzepatide injection), type 2 diabetes dosing.
  3. Jastreboff AM, et al. SURMOUNT-1 (tirzepatide for obesity). N Engl J Med. 2022;387:205–216.

Educational only — not medical advice. Tirzepatide is a prescription medicine; dosing must be set and adjusted by a licensed clinician. Refer to the current FDA prescribing information.